Journal of Translational Medicine · 2014 · 51 citations · 28 references
MedicineOncologyPharmacologyGynecologic OncologyMolecular OncologyOncogenesCytotoxic ChemotherapyMyc Family OncogenesOncogene ActivationOncogenic Signaling PathwaysOvarian CancerPharmacodynamics Of Anticancer AgentsAnnexin V AssaysG1 Cell-cycle ArrestG1 Phase ArrestMyc InhibitorsMyc Proto-oncogeneOvarian Cancer TreatmentPrimary Ovarian CarcinomaTherapeutic Targeting Of Myc
Epithelial ovarian carcinoma is the most lethal gynecological cancer due to its silent onset and recurrence with resistance to chemotherapy. Overexpression of oncogene c-Myc is one of the most frequently encountered events present in ovarian carcinoma. Disrupting the function of c-Myc and its downstream target genes is a promising strategy for cancer therapy. Our objective was to evaluate the potential effects of small-molecule c-Myc inhibitor, 10058-F4, on ovarian carcinoma cells and the underlying mechanisms by which 10058-F4 exerts its actions. Using MTT assay, colony formation, flow cytometry and Annexin V FITC assays, we found that 10058-F4 significantly inhibited cell proliferation of both SKOV3 and Hey ovarian cancer cells in a dose dependent manner through induction of apoptosis and cell cycle G1 arrest. Treatment with 10058-F4 reduced cellular ATP production and ROS levels in SKOV3 and Hey cells. Consistently, primary cultures of ovarian cancer treated with 10058-F4 showed induction of caspase-3 activity and inhibition of cell proliferation in 15 of 18 cases. The response to 10058-F4 was independent the level of c-Myc protein over-expression in primary cultures of ovarian carcinoma. These novel findings suggest that the growth of ovarian cancer cells is dependent upon c-MYC activity and that targeting c-Myc-Max heterodimerization could be a potential therapeutic strategy for ovarian cancer.
28
Donald M. Miller, Shelia D. Thomas, Ashraful Islam et al. · Clinical Cancer Research · 2012 · 854 citations · Full text
Medicine, Cancer Biology, Oncology +17
Jung‐whan Kim, Ping Gao, Yen-Chun Liu et al. · Molecular and Cellular Biology · 2007 · 641 citations · Full text
Medicine, Cancer Biology, Oncology +17
Low molecular weight inhibitors of Myc–Max interaction and function
Xiaoying Yin, Christine Giap, John S. Lazo et al. · Oncogene · 2003 · 430 citations
Intracellular ATP Levels Are a Pivotal Determinant of Chemoresistance in Colon Cancer Cells
Yunfei Zhou, Federico Tozzi, Jinyu Chen et al. · Cancer Research · 2011 · 377 citations · Full text
Medicine, Cancer Biology, Oncology +17